melanotan 2: the unapproved non-selective melanocortin agonist

melanotan 2 is a synthetic cyclic heptapeptide analog of alpha-MSH developed at the University of Arizona in the late 1980s by the Hruby-Hadley team. it activates four of the five melanocortin receptors and produces overlapping pigmentation, appetite, and sexual-behavior effects. it has no FDA, EMA, MHRA, TGA, or HPRA approval and is classified as illegal to sell for human use in those jurisdictions.

what is melanotan 2?

melanotan 2 has the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, a cyclic seven-residue peptide locked into a rigid ring by a lactam bridge between the aspartate side chain and the lysine side chain. that constraint produces a molecule more than 1000 times more potent than native alpha-MSH in classical frog-skin bioassays.

the design strategy was to truncate alpha-MSH down to its minimal active core (residues 4-10), substitute methionine 4 with norleucine to prevent oxidation, substitute L-phenylalanine 7 with D-phenylalanine to increase potency and resist enzymatic cleavage, and cyclize the molecule via a lactam bridge between aspartate at position 5 and lysine at position 10 [1]. the result is a small, rigid, protease-resistant peptide that retains the His-D-Phe-Arg-Trp pharmacophore and engages multiple melanocortin receptors with high potency. the molecule is structurally distinct from melanotan 1 (afamelanotide), which is linear and 13 residues long. it is also structurally distinct from PT-141 (bremelanotide), its near-identical cyclic descendant that differs only in the C-terminal residue (free acid versus amide) and that shift reorients receptor preference toward MC4R and MC3R.

the discovery of melanotan 2 belongs to the Hruby chemistry and Hadley pharmacology collaboration at the University of Arizona in the 1980s. the first human pilot trial was Dorr 1996 in three volunteers, which established subcutaneous dosing and documented visible tanning [2]. Palatin Technologies subsequently ceased melanotan 2 development as a drug candidate and pivoted to the structural derivative PT-141 (bremelanotide), which was engineered for selective MC4R-mediated sexual function.

how does it work?

melanotan 2 is a non-selective full agonist at MC1R, MC3R, MC4R, and MC5R, with essentially no activity at MC2R (the ACTH receptor that mediates cortisol release). MC1R activation drives eumelanin synthesis in melanocytes. MC3R and MC4R activation in the hypothalamus modulates appetite and sexual behavior. MC5R activation affects exocrine gland function.

the pigmentation pathway starts at MC1R on the melanocyte surface. binding activates Gs, raises cAMP, activates protein kinase A, phosphorylates CREB, and drives transcription of MITF, the master regulator of melanocyte gene expression. MITF in turn upregulates tyrosinase and downstream enzymes, shifting melanin synthesis toward eumelanin (the photoprotective brown-black pigment) and away from pheomelanin (the red-yellow pigment that can generate reactive oxygen species under UV) [3]. the appetite and sexual-behavior effects emerge from central MC3R and MC4R activation. melanotan 2 crosses the blood-brain barrier and activates MC4R neurons in the arcuate and paraventricular nuclei of the hypothalamus, reducing food intake and modulating energy expenditure. the same central activity engages sexual-arousal circuitry: the unexpected discovery of erections in male volunteers in the 1996-1998 Wessells studies redirected the entire melanocortin drug development field toward PT-141.

the non-selectivity is the source of both the broad effect profile and the safety concerns. unlike afamelanotide (engineered for MC1R) or PT-141 (engineered for MC4R), melanotan 2 cannot separate tanning from appetite from sexual arousal from cardiovascular effects from gland-secretion effects. the entire melanocortin receptor family is engaged simultaneously, and there is no straightforward way to dial in one effect without the others.

what does the evidence show?

the human evidence base is small: a 1996 pilot Phase 1 in three volunteers for tanning, and two double-blind placebo-controlled crossover studies by Wessells in 1998 (n=10) and 2000 (n=20) for erectile dysfunction. no controlled human evidence exists for cosmetic-tanning safety, appetite endpoints, or chronic-use outcomes. the post-marketing record consists of case reports of serious adverse events.

Dorr and colleagues published the foundational Phase 1 in 1996 in three male volunteers, demonstrating visible tanning after low-dose subcutaneous administration over two weeks [2]. Wessells 1998 was the first double-blind crossover in 10 men with psychogenic ED, reporting clinically apparent erections in 8 of 10 men on melanotan 2 with mean tip rigidity over 80 percent lasting 38 minutes versus 3 minutes for placebo [4]. Wessells 2000 extended the result to 20 men with mixed psychogenic and organic ED, confirming erectile response in 17 of 20 men without sexual stimulation and reporting increased sexual desire in 68 percent of melanotan 2 doses versus 19 percent of placebo doses [5]. no subsequent large-scale tanning trial was ever conducted. Palatin Technologies abandoned melanotan 2 development in 2000 in favor of PT-141, and the molecule moved into the gray-market peptide research economy.

the post-2000 case-report literature is the most clinically relevant evidence base. Nelson 2012 reported systemic toxicity and rhabdomyolysis after melanotan 2 injection [6]. Peters and Hadimeri 2020 described a renal infarction case [7]. Kaski 2013 reported posterior reversible encephalopathy syndrome associated with use. Hjuler and Gronhoj 2014 documented a melanoma case associated with melanotan 2 use [8]. these case reports do not establish causal frequency in the broader user population, but they characterize the spectrum of serious events that the case-report literature has captured.

regulatory status

melanotan 2 has no FDA, EMA, MHRA, TGA, or HPRA approval for any indication. the TGA in Australia has actively pursued enforcement, requesting removal of thousands of unlawful melanotan advertisements from digital platforms in 2023 and 2024. the HPRA in Ireland has issued public safety notices warning about the product. it is sold only as a research chemical or in unregulated gray markets.

the important regulatory contrast is with the related approved molecules. PT-141 (bremelanotide), the structural metabolite of melanotan 2 with a free-acid C-terminus, is FDA approved as Vyleesi for HSDD in premenopausal women. melanotan 1 (afamelanotide) is FDA approved as SCENESSE for erythropoietic protoporphyria. setmelanotide is FDA approved as Imcivree for rare monogenic obesity syndromes. all three are receptor-narrowed melanocortin agonists with defined indications and structured trial programs. melanotan 2 has none of those features. product quality in the gray market is uncontrolled. surveys of online melanotan 2 marketplaces have repeatedly identified material lacking authentic identity documentation, with batch-to-batch variability that compounds the underlying pharmacologic risk.

safety profile and side effects

commonly reported effects include nausea, focal hyperpigmentation, darkening and changes in pre-existing nevi, spontaneous erections, decreased appetite, transient blood pressure changes, and injection-site reactions. serious case reports include rhabdomyolysis, renal infarction, posterior reversible encephalopathy syndrome, and melanoma. chronic-use safety is essentially uncharacterized.

the most concerning long-term concern is the relationship to melanoma. the Hjuler 2014 case report described melanoma in a melanotan 2 user; the mechanistic argument is that broad melanocortin agonism in the presence of dysplastic nevi can theoretically promote malignant transformation, but the case-report literature cannot establish frequency or causality in the broader population. a JAAD 2025 qualitative interview study of 29 self-reported users (mean age 39.4 years) found that participants were "generally unconcerned with long-term adverse effects" and frequently perceived melanotan 2 as protective against skin cancer, a perception that the evidence does not support. the cardiovascular signal includes transient blood pressure increases similar to those that ended the intranasal PT-141 program. focal hyperpigmentation of the face, gingiva, and breasts is mechanistically expected from MC1R activation and is more pronounced than with PT-141. nausea is mechanistically expected from MC4R activation and is the most common acute side effect.

where it fits in peptide therapy

melanotan 2 sits in the melanocortin agonist family as the chemistry parent of PT-141 (bremelanotide) and as the cyclic non-selective counterpart to melanotan 1 (afamelanotide). understanding where it fits means understanding why receptor-selective descendants exist: melanotan 2's non-selectivity is the problem that the entire subsequent drug development effort tried to solve.

the closest structural relative is PT-141 (bremelanotide), which differs only in the C-terminal residue. PT-141 was engineered to retain the sexual-behavior effect at MC4R while reducing MC1R-mediated tanning, and the resulting receptor-narrowed molecule completed Phase 3 development and received FDA approval. that is the cleanest example of how receptor selectivity converts an unapproved gray-market peptide into a regulated drug.

the linear sibling is melanotan 1 (afamelanotide), also FDA approved (as SCENESSE) for erythropoietic protoporphyria. it shares the alpha-MSH heritage but takes the opposite design path: linear rather than cyclic, MC1R-leaning rather than non-selective, designed to amplify photoprotection without the central nervous system effects that define melanotan 2. setmelanotide (Imcivree) is the third regulated melanocortin agonist, MC4R-selective and approved for rare monogenic obesity. together, the four molecules are a worked example of how receptor selectivity reshapes the therapeutic profile and regulatory pathway. for broader context on melanocortin biology and the POMC system, see our free peptides and your body module.